Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Medicine
Published in: BMC Medicine 1/2014

Open Access 01-12-2014 | Editorial

Open questions in autoimmunity: discussions from the 2013 Controversies in Rheumatology and Autoimmunity Meeting

Authors: Carlo Selmi, Yehuda Shoenfeld

Published in: BMC Medicine | Issue 1/2014

Login to get access

Abstract

The recent CORA (Controversies in Rheumatology and Autoimmunity) meeting held in 2013 represented a unique opportunity for rheumatologists to address several topics. Among these, four topics include: (i) the role of epigenetic changes in the pathogenesis of rheumatoid arthritis (RA), as shown by studies in monozygotic twins; (ii) the cardiovascular and atherosclerotic risk in patients with RA treated with biologics; (iii) the use of new biomarkers for the diagnosis and follow-up of RA and other autoimmune diseases, as represented by the new automatic machines for anti-nuclear antibodies detection, or ultrasound imaging to follow RA progression; and (iv) the latest guidelines on how to use and manage biologic therapies in RA and other autoimmune diseases, such as lupus. In summary, we will herein present these topics of discussion and underline the conclusions obtained by rheumatologists during the 2013 CORA Meeting.
Literature
1.
Selmi C: Autoimmunity in 2012. Clin Rev Allergy Immunol. 2013, 45: 290-301. 10.1007/s12016-013-8386-7.CrossRefPubMed
2.
Bogdanos DP, Smyk DS, Rigopoulou EI, Mytilinaiou MG, Heneghan MA, Selmi C, Gershwin ME: Twin studies in autoimmune disease: genetics, gender and environment. J Autoimmun. 2012, 38: J156-J169. 10.1016/j.jaut.2011.11.003.CrossRefPubMed
3.
Selmi C, Lu Q, Humble MC: Heritability versus the role of the environment in autoimmunity. J Autoimmun. 2012, 39: 249-252. 10.1016/j.jaut.2012.07.011.CrossRefPubMed
4.
5.
Costenbader KH, Gay S, Alarcon-Riquelme ME, Iaccarino L, Doria A: Genes, epigenetic regulation and environmental factors: which is the most relevant in developing autoimmune diseases?. Autoimmun Rev. 2012, 11: 604-609. 10.1016/j.autrev.2011.10.022.CrossRefPubMed
6.
De Santis M, Selmi C: The therapeutic potential of epigenetics in autoimmune diseases. Clin Rev Allergy Immunol. 2012, 42: 92-101. 10.1007/s12016-011-8293-8.CrossRefPubMed
7.
Liu Y, Li H, Xiao T, Lu Q: Epigenetics in immune-mediated pulmonary diseases. Clin Rev Allergy Immunol. 2013, 45: 314-330. 10.1007/s12016-013-8398-3.CrossRefPubMed
8.
Luo Y, Wang Y, Wang Q, Xiao R, Lu Q: Systemic sclerosis: genetics and epigenetics. J Autoimmun. 2013, 41: 161-167.CrossRefPubMed
9.
Ngalamika O, Zhang Y, Yin H, Zhao M, Gershwin ME, Lu Q: Epigenetics, autoimmunity and hematologic malignancies: a comprehensive review. J Autoimmun. 2012, 39: 451-465. 10.1016/j.jaut.2012.09.002.CrossRefPubMed
10.
Thabet Y, Canas F, Ghedira I, Youinou P, Mageed RA, Renaudineau Y: Altered patterns of epigenetic changes in systemic lupus erythematosus and auto-antibody production: is there a link?. J Autoimmun. 2012, 39: 154-160. 10.1016/j.jaut.2012.05.015.CrossRefPubMed
11.
Zhang Y, Zhao M, Sawalha AH, Richardson B, Lu Q: Impaired DNA methylation and its mechanisms in CD4(+)T cells of systemic lupus erythematosus. J Autoimmun. 2013, 41: 92-99.CrossRefPubMed
12.
13.
Coit P, Jeffries M, Altorok N, Dozmorov MG, Koelsch KA, Wren JD, Merrill JT, McCune WJ, Sawalha AH: Genome-wide DNA methylation study suggests epigenetic accessibility and transcriptional poising of interferon-regulated genes in naive CD4+ T cells from lupus patients. J Autoimmun. 2013, 43: 78-84.CrossRefPubMedPubMedCentral
14.
Pengo V, Banzato A, Denas G, Jose SP, Bison E, Hoxha A, Ruffatti A: Correct laboratory approach to APS diagnosis and monitoring. Autoimmun Rev. 2013, 12: 832-834. 10.1016/j.autrev.2012.11.008.CrossRefPubMed
15.
Priori R, Scrivo R, Brandt J, Valerio M, Casadei L, Valesini G, Manetti C: Metabolomics in rheumatic diseases: the potential of an emerging methodology for improved patient diagnosis, prognosis, and treatment efficacy. Autoimmun Rev. 2013, 12: 1022-1030. 10.1016/j.autrev.2013.04.002.CrossRefPubMed
16.
Rossi D, Russo A, Manna E, Binello G, Baldovino S, Sciascia S, Roccatello D: The role of nail-videocapillaroscopy in early diagnosis of scleroderma. Autoimmun Rev. 2013, 12: 821-825. 10.1016/j.autrev.2012.11.006.CrossRefPubMed
17.
Matsuura E, Lopez LR, Shoenfeld Y, Ames PR: β2-glycoprotein I and oxidative inflammation in early atherogenesis: a progression from innate to adaptive immunity?. Autoimmun Rev. 2012, 12: 241-249. 10.1016/j.autrev.2012.04.003.CrossRefPubMed
18.
Siegel D, Devaraj S, Mitra A, Raychaudhuri SP, Raychaudhuri SK, Jialal I: Inflammation, atherosclerosis, and psoriasis. Clin Rev Allergy Immunol. 2013, 44: 194-204. 10.1007/s12016-012-8308-0.CrossRefPubMed
19.
Singh RP, Massachi I, Manickavel S, Singh S, Rao NP, Hasan S, Mc Curdy DK, Sharma S, Wong D, Hahn BH, Rehimi H: The role of miRNA in inflammation and autoimmunity. Autoimmun Rev. 2013, 12: 1160-1165. 10.1016/j.autrev.2013.07.003.CrossRefPubMed
20.
Iborra M, Bernuzzi F, Invernizzi P, Danese S: MicroRNAs in autoimmunity and inflammatory bowel disease: crucial regulators in immune response. Autoimmun Rev. 2012, 11: 305-314. 10.1016/j.autrev.2010.07.002.CrossRefPubMed
21.
Saito Y, Saito H, Liang G, Friedman JM: Epigenetic alterations and microRNA misexpression in cancer and autoimmune diseases: a critical review. Clin Rev Allergy Immunol. in press
22.
Ando Y, Yang GX, Kenny TP, Kawata K, Zhang W, Huang W, Leung PS, Lian ZX, Okazaki K, Ansari AA, He XS, Invernizzi P, Ridgway WM, Lu Q, Gershwin ME: Overexpression of microRNA-21 is associated with elevated pro-inflammatory cytokines in dominant-negative TGF-beta receptor type II mouse. J Autoimmun. 2013, 41: 111-119.CrossRefPubMedPubMedCentral
23.
Hahn BH, Grossman J, Chen W, McMahon M: The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: roles of inflammation and dyslipidemia. J Autoimmun. 2007, 28: 69-75. 10.1016/j.jaut.2007.02.004.CrossRefPubMed
24.
Soltesz P, Kerekes G, Der H, Szucs G, Szanto S, Kiss E, Bodolay E, Zeher M, Timar O, Szodoray P, Szegedi G, Szekanecz Z: Comparative assessment of vascular function in autoimmune rheumatic diseases: considerations of prevention and treatment. Autoimmun Rev. 2011, 10: 416-425. 10.1016/j.autrev.2011.01.004.CrossRefPubMed
25.
Pengo V, Ruiz-Irastorza G, Denas G, Andreoli L, Khamashta M, Tincani A: High intensity anticoagulation in the prevention of the recurrence of arterial thrombosis in antiphospholipid syndrome: 'PROS' and 'CONS'. Autoimmun Rev. 2012, 11: 577-580. 10.1016/j.autrev.2011.10.016.CrossRefPubMed
26.
27.
Doria A, Dayer JM, Punzi L: Autoinflammatory diseases: how to put the fire inside the body out?. Autoimmun Rev. 2012, 12: 1-4. 10.1016/j.autrev.2012.07.013.CrossRefPubMed
28.
Rigante D: The fresco of autoinflammatory diseases from the pediatric perspective. Autoimmun Rev. 2012, 11: 348-356. 10.1016/j.autrev.2011.10.008.CrossRefPubMed
29.
Zen M, Gatto M, Domeneghetti M, Palma L, Borella E, Iaccarino L, Punzi L, Doria A: Clinical guidelines and definitions of autoinflammatory diseases: contrasts and comparisons with autoimmunity-a comprehensive review. Clin Rev Allergy Immunol. 2013, 45: 227-235. 10.1007/s12016-013-8355-1.CrossRefPubMed
30.
Chamorro AJ, Marcos M, Miron-Canelo JA, Cervera R, Espinosa G: Val247Leu beta2-glycoprotein-I allelic variant is associated with antiphospholipid syndrome: systematic review and meta-analysis. Autoimmun Rev. 2012, 11: 705-712. 10.1016/j.autrev.2011.12.006.CrossRefPubMed
31.
de la Torre YM, Pregnolato F, D'Amelio F, Grossi C, Di Simone N, Pasqualini F, Nebuloni M, Chen P, Pierangeli S, Bassani N, Ambrogi F, Borghi MO, Vecchi A, Locati M, Meroni PL: Anti-phospholipid induced murine fetal loss: novel protective effect of a peptide targeting the beta2 glycoprotein I phospholipid-binding site, Implications for human fetal loss. J Autoimmun. 2012, 38: J209-J215. 10.1016/j.jaut.2011.11.009.CrossRefPubMed
32.
Mahler M, Norman GL, Meroni PL, Khamashta M: Autoantibodies to domain 1 of beta 2 glycoprotein 1: a promising candidate biomarker for risk management in antiphospholipid syndrome. Autoimmun Rev. 2012, 12: 313-317. 10.1016/j.autrev.2012.05.006.CrossRefPubMed
33.
Tozzoli R, Villalta D: Autoantibody profiling of patients with antiphospholipid syndrome using an automated multiplexed immunoassay system. Autoimmun Rev. 2014, 13: 59-63. 10.1016/j.autrev.2013.08.007.CrossRefPubMed
34.
Conrad K, Roggenbuck D, Reinhold D, Sack U: Autoantibody diagnostics in clinical practice. Autoimmun Rev. 2012, 11: 207-211. 10.1016/j.autrev.2011.05.014.CrossRefPubMed
35.
Villalta D, Imbastaro T, Di Giovanni S, Lauriti C, Gabini M, Turi MC, Bizzaro N: Diagnostic accuracy and predictive value of extended autoantibody profile in systemic sclerosis. Autoimmun Rev. 2012, 12: 114-120. 10.1016/j.autrev.2012.07.005.CrossRefPubMed
36.
37.
van Sijl AM, Peters MJ, Knol DL, de Vet RH, Sattar N, Dijkmans BA, Smulders YM, Nurmohamed MT: The effect of TNF-alpha blocking therapy on lipid levels in rheumatoid arthritis: a meta-analysis. Semin Arthritis Rheum. 2011, 41: 393-400. 10.1016/j.semarthrit.2011.04.003.CrossRefPubMed
38.
39.
Gatto M, Kiss E, Naparstek Y, Doria A: In/Off label use of biologic therapy in systemic lupus erythematosus. BMC Med. 2014, 12: 30-10.1186/1741-7015-12-30.CrossRefPubMedPubMedCentral
40.
Mocsai A, Kovacs L, Gergely P: What is the future of targeted therapy in rheumatology: biologics or small molecules?. BMC Med. 2014, 12: 43-10.1186/1741-7015-12-43.CrossRefPubMedPubMedCentral
41.
Meroni PL, Bizzaro N, Cavazzana I, Borghi MO, Tincani A: Automated tests of ANA immunofluorescence as throughput autoantibody detection technology: strengths and limitations. BMC Med. 2014, 12: 38-10.1186/1741-7015-12-38.CrossRefPubMedPubMedCentral
42.
Melegari A, Bonaguri C, Russo A, Luisita B, Trenti T, Lippi G: A comparative study on the reliability of an automated system for the evaluation of cell-based indirect immunofluorescence. Autoimmun Rev. 2012, 11: 713-716. 10.1016/j.autrev.2011.12.010.CrossRefPubMed
43.
Bizzaro N, Antico A, Platzgummer S, Tonutti E, Bassetti D, Pesente F, Tozzoli R, Tampoia M, Villalta D, Study Group on Autoimmune Diseases of the Italian Society of Laboratory Medicine I: Automated antinuclear immunofluorescence antibody screening: a comparative study of six computer-aided diagnostic systems. Autoimmun Rev. 2014, 13: 292-298. 10.1016/j.autrev.2013.10.015.CrossRefPubMed
44.
Koenig M, Dieude M, Senecal JL: Predictive value of antinuclear autoantibodies: the lessons of the systemic sclerosis autoantibodies. Autoimmun Rev. 2008, 7: 588-593. 10.1016/j.autrev.2008.06.010.CrossRefPubMed
45.
Moinzadeh P, Nihtyanova SI, Howell K, Ong VH, Denton CP: Impact of hallmark autoantibody reactivity on early diagnosis in scleroderma. Clin Rev Allergy Immunol. 2012, 43: 249-255. 10.1007/s12016-012-8331-1.CrossRefPubMed
46.
Meroni PL, Schur PH: ANA screening: an old test with new recommendations. Ann Rheum Dis. 2010, 69: 1420-1422. 10.1136/ard.2009.127100.CrossRefPubMed
47.
48.
Shi J, van Veelen PA, Mahler M, Janssen GM, Drijfhout JW, Huizinga TW, Toes RE, Trouw LA: Carbamylation and antibodies against carbamylated proteins in autoimmunity and other pathologies. Autoimmun Rev. 2014, 13: 225-230. 10.1016/j.autrev.2013.10.008.CrossRefPubMed
49.
Acharya NK, Nagele EP, Han M, Coretti NJ, DeMarshall C, Kosciuk MC, Boulos PA, Nagele RG: Neuronal PAD4 expression and protein citrullination: possible role in production of autoantibodies associated with neurodegenerative disease. J Autoimmun. 2012, 38: 369-380. 10.1016/j.jaut.2012.03.004.CrossRefPubMed
50.
Auger I, Charpin C, Balandraud N, Martin M, Roudier J: Autoantibodies to PAD4 and BRAF in rheumatoid arthritis. Autoimmun Rev. 2012, 11: 801-803. 10.1016/j.autrev.2012.02.009.CrossRefPubMed
Metadata
Title
Open questions in autoimmunity: discussions from the 2013 Controversies in Rheumatology and Autoimmunity Meeting
Authors
Carlo Selmi
Yehuda Shoenfeld
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Medicine / Issue 1/2014
Electronic ISSN: 1741-7015
DOI
https://doi.org/10.1186/1741-7015-12-50

Other articles of this Issue 1/2014

BMC Medicine 1/2014 Go to the issue

Question and Answer

Video Q&A: Tobacco-related mortality: past, present and future. An interview with Alan Lopez

Commentary

The atrial fibrillation epidemic is approaching the physician's door: will mobile technology improve detection?

Commentary

Why public health people are more worried than excited over e-cigarettes

Editorial

BMC Medicine: a decade of open access medical research

Research article

Treatment of vascular risk factors in patients with a diagnosis of Alzheimer’s disease: a systematic review

Minireview

Molecular determinants of context-dependent progesterone receptor action in breast cancer